Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Glandular Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Glandular Cell Neoplasm

Cancer Family

Glandular Cell Neoplasm

CI-CAN-00000188Explore in graph →

Non-malignant2,825 active trials43 approved drugs426 evidence items

NCIt: C7132

Overview
Statistics
Survival
Genomics166
Variants & evidence426
Drugs106
Trials10211
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (384)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 151–175 of 384 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
· J Thorac Oncol · 2012 · PMID 22895145 · validated civic_curation pubmed
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
· Mol Cancer Ther · 2013 · PMID 23371856 · validated civic_curation pubmed
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
· Sci Transl Med · 2013 · PMID 24353160 · validated civic_curation pubmed
Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma.
· Respir Investig · 2016 · PMID 27566387 · validated civic_curation pubmed
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
· N Engl J Med · 2010 · PMID 20979473 · validated civic_curation pubmed
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
· Sci Transl Med · 2012 · PMID 22277784 · validated civic_curation pubmed
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
· Ann Oncol · 2016 · PMID 26598547 · validated civic_curation

Showing 151–175 of 384 publications

← Previous
1
…
6
7
8
…
16
Next →

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.

· Lung Cancer · 2015 · PMID 26559459 · validated civic_curation pubmed

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.

· Int J Gynaecol Obstet · 2008 · PMID 18555254 · validated civic_curation pubmed

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

· N Engl J Med · 2013 · PMID 23724914 · validated civic_curation pubmed

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib.

· Case Rep Oncol · 2014 · PMID 24987354 · validated civic_curation pubmed

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

· J Clin Oncol · 2015 · PMID 26324360 · validated civic_curation pubmed

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

· Cancer Discov · 2016 · PMID 26546295 · validated civic_curation pubmed

Genotype-phenotype correlations in von Hippel-Lindau disease.

· Hum Mutat · 2007 · PMID 17024664 · validated civic_curation pubmed

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.

· Cancer Discov · 2018 · PMID 29802158 · validated civic_curation pubmed

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

· Cancer Discov · 2016 · PMID 27102076 · validated civic_curation pubmed

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib.

· Front Oncol · 2022 · PMID 36419889 · validated civic_curation pubmed

EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.

· Lung Cancer · 2018 · PMID 29290255 · validated civic_curation pubmed

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

· Cancer Discov · 2011 · PMID 22389872 · validated civic_curation pubmed

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

· Cancer Discov · 2015 · PMID 25971939 · validated civic_curation pubmed

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

· Lung Cancer · 2012 · PMID 22325357 · validated civic_curation pubmed

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

· J Clin Oncol · 2016 · PMID 26729443 · validated civic_curation pubmed

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.

· J Thorac Oncol · 2015 · PMID 25789838 · validated civic_curation pubmed

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

· Nat Commun · 2016 · PMID 26883990 · validated civic_curation pubmed

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

· Cancer Discov · 2015 · PMID 25971938 · validated civic_curation pubmed